Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy.

On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network's The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain adjustments. It includes $75 million in the first quarter.

Martha noted the figure could change given new US tariff threats targeting multiple trading partners emerge, saying, "we'll have to re-evaluate that."

He said tariffs remain "pretty meaningful," surging year over year and adding pressure along with higher input costs such as fuel. He underlined that around 80% of  Medtronic plc (NYSE:MDT)'s supply chain and over 90% of R&D are based in the US.

15 States with the Best Healthcare in the US

Martha pointed to growth as a buffer with a 78% revenue jump in cardiac ablation alongside strength in pacemakers, surgical, and spine businesses.

He also said the medtech firm put in $2 billion in acquisitions over the past fiscal year and invests $5 billion to $6 billion annually in innovation.

Medtronic plc (NYSE:MDT) is a medical technology company. It works in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit segments.

While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.